Buse, M.D., from the University of North Carolina School of Medicine in Chapel Hill, and colleagues randomly assigned 2,713 adults with inadequately controlled type 2 diabetes receiving metformin with or without SGLT2i with overweight or obesity to receive cagrilintide-semaglutide, semaglutide, cagrilintide, or placebo for 68 weeks
Yes, switching between forms is possible
In addition to its role in maintaining weight loss, Semaglutides benefits extend to improving overall metabolic health
Side effects to be aware of and how best to manage them to optimize your GLP-1 journey
DOI: 10.1016/j.metabol.2007.03.005
Novo Nordisks newest drug, CagriSema, led to greater weight loss than semaglutide, according to results presented Sunday at the conference